The Role of TOP2B and DNA Damage/Repair in Cancer

Dear Colleagues,

Accumulating evidence demonstrating that transcriptional programs require the class II topoisomerase TOP2B and DNA damage and repair factors challenges the simplified view of these programs in favor of one involving large-scale genomic reorganization. Importantly, DNA damage mediated by TOP2B seems to represent a vulnerability for cancer cells and a better mechanistic understanding of these processes may lead to effective cancer prevention and treatment strategies.

In this Special Issue, we aim to highlight recent advances in understanding TOP2B-mediated DNA damage and repair with respect to cancer biology, treatment paradigms, carcinogenesis, and personalized medicine.

TOP2B has been shown to be involved in androgen-induced genomic rearrangements, yet the mechanisms through which TOP2B-mediated DNA double strand breaks occur have not yet been elucidated. Exciting developments in high resolution assays to study genome reorganization show promise in understanding TOP2B in cancer biology and topoisomerase-targeted therapies.

We invite the submission of original articles to this Special Issue of the Journal of Personalized Medicine that aim to uncover insights into the role of TOP2B in DNA damage and repair in cancers. We welcome studies ranging from mechanistic insights and innovative techniques to novel cancer treatment strategies.

Assist. Prof. Jonathan B. Coulter
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Topoisomerase II
• TOP2B
• DNA damage
• DNA repair
• Transcription
• Cancer
• DNA double strand breaks
• Topoisomerase poisons